Vaccine Development


Last updated: 2021 Nov 12
Total hit(s): 11
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Mice immunized with adjuvanted NVX-CoV2373 had significantly higher anti-S IgG titers with good neutralizing activity and blocked the hACE-2 receptor. Mice immunized with adjuvanted vaccine (both single and booster dose) were significantly protected from weight loss when compared to the palcebo treated mice.
33446655
(Nat Commun)
PMID
33446655
Date of Publishing: 2021 Jan 14
Title SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Author(s) nameTian JH, Patel N et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 5
Date of Entry 2021 Nov 12


Olive baboons immunized with adjuvanted NVX-CoV2373 showed high titer Anti-S antibodies with good neutralizing activity and blocked the hACE-2 receptor. NVX-CoV2373 vaccine induced binding and functional antibodies in a nonhuman primate at levels comparable or higher than individuals recovered from COVID-19 and is a promisin vaccine candidate
33446655
(Nat Commun)
PMID
33446655
Date of Publishing: 2021 Jan 14
Title SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Author(s) nameTian JH, Patel N et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 5
Date of Entry 2021 Nov 12


A multi-epitope vaccine was designed based on reverse-vaccinology approach. This vaccine was able to elicit a humoral and cellular immune response against SARS-CoV-2 infection.
33264668
(Infect Genet Evol)
PMID
33264668
Date of Publishing: 2020 Nov 29
Title Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes
Author(s) nameJain N, Shankar U et al.
Journal Infect Genet Evol
Impact factor
2.67
Citation count: 1
Date of Entry 2021 Nov 12


SARS-CoV-2 RBD219-N1C1 vaccine candidate induced high titers of IgG virus-neutralizing antibodies and T-cell responses in immunized mice. The vaccine was also able to induce high levels of IFN-gamma, IL-6 and IL-12 cytokines. The deleted and altered residues are structurally distinct from immunogenic epitopes, particularly the RBD's receptor-binding motif (RBM). There was no correlation between the amount of Alhydrogel to which the RBD was bound and the interaction with hACE-2-Fc, implying that the RBD proteins' surface density on the Alhydrogel had no effect on the presentation of ACE binding sites.
33847226
(Hum Vaccin Immunother)
PMID
33847226
Date of Publishing: 2021 Apr 13
Title SARSCoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
Author(s) namePollet J, Chen WH et al.
Journal Hum Vaccin Immunother
Impact factor
4.7
Citation count: 7
Date of Entry 2021 Oct 31


Immunization of mice (C57BL/6 and BALB/c strains) and Pigs with RBD-SpyVLP vaccine showed strong dose-dependent neutralising antibody response. The polyclonal antibody response could recognize key epitopes on RBD (Receptor-Binding Domain). Besides, this vaccine is found to be thermostable making it easier for transportation globally.
33483491
(Nat Commun)
PMID
33483491
Date of Publishing: 2021 Jan 22
Title A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Author(s) nameTan TK, Rijal P et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 1
Date of Entry 2021 Oct 31


A prefusion-stabilized SARS-CoV-2 spike protein, S-2P was most successful in generating antibodies that neutralised pseudovirus and wild-type live virus when combined with CpG 1018 and aluminium hydroxide adjuvants, with no vaccine-related side effects.
33208827
(Sci Rep)
PMID
33208827
Date of Publishing: 2020 Nov 18
Title Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Author(s) nameKuo TY, Lin MY et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 4
Date of Entry 2021 Oct 31


Nonhuman primates vaccinated with mRNA-1273 developed strong antibody and cell-based immune responses. There was immediate protection in both the upper and lower airways, as well as no pathologic alterations in the lungs. In accordance with the obtained results of mRNA vaccine on non-primates, a clinical study on a small human population is important to know its specific response.
32722908
(N Engl J Med)
PMID
32722908
Date of Publishing: 2020 Oct 15
Title Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Author(s) nameCorbett KS, Flynn B et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 46
Date of Entry 2021 Oct 31


The immunogenecity of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) was tested at three different dosages. At all doses examined, the seroconversion rate reached 100% in mice 7 days after vaccination and 21 days in rabbits, guinea pigs, and rats. When compared to one- and two-dose vaccination regimens, a three-dose vaccination regimen showed better immunogenecity in all animal models studied. Cynomoglus monkeys, rabbit, guinea pigs, rats and mice were immunised with 8, 4 or 2 micro grams of the inactivated BBIBP-CorV.
32778225
(Cell)
PMID
32778225
Date of Publishing: 2020 Aug 6
Title Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Author(s) nameWang H, Zhang Y et al.
Journal Cell
Impact factor
27.35
Citation count: 50
Date of Entry 2021 Oct 31


Rhesus macaques were immunised with the BBIBP-CorV vaccine at low dose (2ug/dose) and high dose (8ug/dose). Both the vaccine doses elicited a good neutralising antibody titre and offered protection against intrateacheal SARS-CoV-2 challenge.
32778225
(Cell)
PMID
32778225
Date of Publishing: 2020 Aug 6
Title Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Author(s) nameWang H, Zhang Y et al.
Journal Cell
Impact factor
27.35
Citation count: 50
Date of Entry 2021 Oct 31


Rhesus macaques vaccinated with a DNA vaccine, developed a good celluar and humoral immune response. Neutralising anitbody titers in vaccinated animals was comparable to convalescent people. Vaccinated animals challenged with SARS-CoV-2 virus showed a significant reduction (>3.1 and >3.7 log 10 ) in the viral loads in the lungs and nasal mucosa when compared to control animals. 35 Rhesus macaques (6 to 12 years old) were immunized with DNA vaccines in the following groups: S (N = 4), S.dCT (N = 4), S.dTM(N=4),S1(N=4),RBD(N=4),S.dTM, PP (N=5), Sham controls(N=10)
32434945
(Science)
PMID
32434945
Date of Publishing: 2020 Aug 14
Title DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Author(s) nameYu J, Tostanoski LH et al.
Journal Science
Impact factor
20.57
Citation count: 445
Date of Entry 2021 Oct 31


a single dose of the INO-4800 DNA vaccine was able to induce antigen specific T cell responses and neutralising antibodies in mice and guinea pigs.
32433465
(Nat Commun)
PMID
32433465
Date of Publishing: 2020 May 20
Title Immunogenicity of a DNA vaccine candidate for COVID-19
Author(s) nameSmith TRF, Patel A et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 223
Date of Entry 2021 Oct 31